K-Ras mutation in transitional cell carcinoma of urinary bladder

被引：16

作者：

Ayan S. ^{[1
]}

Gokce G. ^{[1
]}

Kilicarslan H. ^{[1
]}

Ozdemir O. ^{[1
]}

Yildiz E. ^{[1
]}

Gultekin E.Y. ^{[1
]}

机构：

[1] Department of Urology, Medical Biology and Genetics and Pathology, Faculty of Medicine, Cumhuriyet University

来源：

International Urology and Nephrology | 2001年 / 33卷 / 2期

关键词：

Bladder cancer; K-RAS gene;

D O I：

10.1023/A:1015213713048

中图分类号：

学科分类号：

摘要：

In the present study it was aimed to investigate the frequency of K-RAS mutation in the human bladder transitional cell carcinoma. For this purpose, tissue specimens obtained from the patients with bladder tumors. Genomic DNAs were isolated and then PCR-SSCP analysis of K-RAS gene were performed. A heterozygous deleted mutation was detected in K-RAS oncogene (exon 2) in agorose gel electrophoresis in one patient and point or substitution mutations are detected using single strand conformational polymorphism (SSCP) in other different patients with bladder cancer (4/14). In conclusion, the frequency of K-RAS mutation is not rare and the role of this mutation in oncogenesis and in infiltration of the urinary bladder wall needs to be confirmed in a larger study.

引用

页码：363 / 367

页数：4

共 25 条

[1] Bos J.L., Ras oncogene in human cancer: A review, Cancer Res, 49, pp. 4682-4689, (1999)
[2] Barbacid M., Ras genes, Ann Rev Biochem, 56, pp. 779-827, (1987)
[3] Almoquera C., Shibata D., Forrester K., Martin J., Arnheim N., Perucho M., Most human carcinomas of the exocrine pancreas contain c-K-ras genes, Cell, 53, pp. 549-554, (1988)
[4] Smit V.T.H.B.M., Boot A.J.M., Smits A.M.M., Fleuren G.J., Cornelisse C.J., Bos J.L., K-ras codon 12 point mutations occur very frequently in pancreatic adenocarcinomas, Nucleic Acids Res, 16, pp. 7773-7782, (1988)
[5] Husgavfel-Pursianien K., Ridanpaa M., Hackman P., Anttila S., Karialainen A., Onfelt A., Boressen A.L., Vanio H., Detection of ras gene mutations in human lung cancer: Comparison of two screening assays based on the polymerase chain rection, Environ Health Perspect, 98, pp. 183-185, (1992)
[6] Zhang F.Z., Steineck, Epidemiology and etiology of bladder cancer, Principles and Practice of Genitourinary Oncology, (1996)
[7] Fujita F., Srivastava S.K., Kraus M.H., Rhim J.S., Tronick S.R., Aaronson S.A., Frequency of molecular alterations affecting ras protoncogenes in human urinary tract tumors, Proc Natl Acad Sci USA, 83, pp. 3849-3853, (1985)
[8] Fujita F., Yoshida O., Yuasa Y., Rhim J.S., Hatanaka M., Aaronson S.A., Ha-ras oncogenes are activated by somatic alterations in human urinary tract tumors, Nature, 309, pp. 464-466, (1984)
[9] Malone P.R., Visvanathan K.V., Ponder B.A., Shearer R.J., Summerhayes I.C., Oncogenes and bladder cancer, BJ Urol, 57, pp. 664-667, (1985)
[10] Czerniak B., Cohen G.L., Etkind P., Deitch D., Simmons H., Herz F., Koss L.G., Concurrent mutations of coding end regulatory sequences of the Ha-ras gene in urinary bladder carcinoma, Human Pathol, 23, pp. 1199-1204, (1992)

← 1 2 3 →